Regulus Therapeutics (RGLS) Issues Earnings Results

Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.07, Fidelity Earnings reports. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative return on equity of 205.48% and a negative net margin of 83,538.89%.

RGLS opened at $1.65 on Friday. Regulus Therapeutics has a 1-year low of $1.57 and a 1-year high of $17.28. The company has a market capitalization of $15.54 million, a PE ratio of -0.14 and a beta of 1.78.

A number of brokerages have issued reports on RGLS. Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday. Wedbush reissued a “hold” rating and issued a $2.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, October 9th. Finally, ValuEngine raised Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Nine research analysts have rated the stock with a hold rating, Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $1.42.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3928919/regulus-therapeutics-rgls-issues-earnings-results.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: Google Finance Portfolio

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing Matthews International  & IBC Advanced Alloys
Comparing Matthews International & IBC Advanced Alloys
Critical Review: Lightwave Logic  versus KushCo
Critical Review: Lightwave Logic versus KushCo
Rcoin  Price Hits $0.0001 on Top Exchanges
Rcoin Price Hits $0.0001 on Top Exchanges
Marijuanacoin  Price Tops $0.0105
Marijuanacoin Price Tops $0.0105
BIO-key International  Releases  Earnings Results
BIO-key International Releases Earnings Results
Bezant Price Down 39.7% Over Last 7 Days
Bezant Price Down 39.7% Over Last 7 Days


Leave a Reply

© 2006-2018 Ticker Report